 Hachiro Sugimoto

Sugimoto's research on E2020 (now called "Donepezil"), an acetylcholinesterase inhibitor, first began at Eisai's Tsukuba Research Laboratories in 1983, because his mother suffered from dementia.At that time, there was a hypothesis suggested that acetylcholines were closely linked to abnormal decreases in memory function in patients with Alzheimer's disease.